bms-986263
Nucleic acidexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 11, 2017 (NCT03142165)
Timeline
Indications
Mechanism of action
- Serpin H1ANTISENSE INHIBITOR
SERPINH1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bms-986263
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04267393 | Phase 2 | Apr 15, 2020 | Bristol-Myers Squibb |
| NCT04225936 | Phase 1 | Jan 10, 2020 | Bristol-Myers Squibb |
| NCT03420768 | Phase 2 | Feb 13, 2018 | Bristol-Myers Squibb |
| NCT03142165 | Phase 1 | May 11, 2017 | Bristol-Myers Squibb |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 4 | 4 | 2 | 2017 |
1 organizations
Page 1 / 1